Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stealth Biotherapeutics Corp Ads (MITO)

Stealth Biotherapeutics Corp Ads (MITO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting

, /PRNewswire/ -- (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction,...

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics to Present at Upcoming Investor Conferences in September

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving...

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights

, /PRNewswire/ -- Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction,...

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving...

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving...

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics Corp (MITO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics to Present at UBS Virtual Global Healthcare Conference

, /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving...

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights

, /PRNewswire/ --  Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction,...

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

, /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving...

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics Corp (MITO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).

MITO : 1.3500 (+2.27%)
Global Market for Cancer Therapies Could Exceed US$220 Billion by 2025

Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the...

SPEX : 1.6300 (-18.09%)
INO : 11.31 (-6.84%)
MITO : 1.3500 (+2.27%)
PFE : 36.17 (-0.60%)
LLY : 146.26 (-1.24%)
OMER : 9.57 (-3.82%)
4 Reasons Why Investors Should Buy Alexion (ALXN) in 2020

Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction.

ACHN : 6.76 (+10.28%)
ALXN : 112.46 (-0.74%)
AMGN : 248.30 (+0.51%)
MITO : 1.3500 (+2.27%)
Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength

Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.

AMGN : 248.30 (+0.51%)
ACHN : 6.76 (+10.28%)
ALXN : 112.46 (-0.74%)
MITO : 1.3500 (+2.27%)
Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance

Alexion (ALXN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

INCY : 87.43 (-3.24%)
ACHN : 6.76 (+10.28%)
ALXN : 112.46 (-0.74%)
MITO : 1.3500 (+2.27%)
Company News For Oct 11, 2019

Companies in the news are: RARX, BBBY, PCG, MITO

PCG : 9.39 (-0.63%)
BBBY : 14.51 (-2.49%)
MITO : 1.3500 (+2.27%)
RARX : 47.99 (-0.03%)
Alexion (ALXN) Collaborates With Stealth BioTherapeutics

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

AMGN : 248.30 (+0.51%)
ALXN : 112.46 (-0.74%)
EIDX : 50.07 (-0.73%)
MITO : 1.3500 (+2.27%)
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

--- If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license -

ALXN : 112.46 (-0.74%)
MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics Enters Oversold Territory

Stealth BioTherapeutics Corp (MITO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

MITO : 1.3500 (+2.27%)
Stealth BioTherapeutics Sees Hammer Chart Pattern: Time to Buy?

Stealth BioTherapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

MITO : 1.3500 (+2.27%)
Hercules Capital Reports First Quarter 2019 Financial Results

--Grew Debt Investment Portfolio by $160.5 Million, Leading to Record Total Debt Investments of $1.91 Billion, at Cost

WFC : 23.26 (-2.35%)
MITO : 1.3500 (+2.27%)
XFOR : 6.66 (+2.78%)
PINS : 40.56 (-1.02%)
WMT : 137.14 (-0.08%)
HTGC : 11.48 (+0.17%)
HCXZ : 25.70 (-0.12%)
HCXY : 26.50 (+0.38%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar